The U.S. Food and Drug Administration has approved Spravato, a nasal spray based on esketamine, as the first stand-alone medication for severe depression. Johnson & Johnson claims patients may experience improvement within 24 hours by targeting the brain’s most abundant neurotransmitter, glutamate. This breakthrough is crucial for those resistant to oral antidepressants or unable to tolerate them. Major depressive disorder affects nearly 8% of U.S. adults annually, making this treatment a significant advancement in healthcare.
Read it at Reuters.
Source: https://www.thedailybeast.com/fda-approves-nose-spray-for-depression